The Wilcoxon signed-rank method tested for differences between patients and controls, area under the curve (AUC) values evaluated patient classifier models, and Pearson's correlation assessed concordance between EEGLAB and Persyst.<h4>Results</h4>Patients with SLC6A1-NDD exhibited significantly elevated delta power (19.4 ± 4.1) compared to controls (14.2 ± 3.0; <i>p</i> < 0.001). The gene discussed is SLC6A1; the disease is Neurodevelopmental delay.